Home / VectraCor – Investor Information

VectraCor – Investor Information

Cardiovascular disease is the number one killer in the United States. According to the American Heart Association (AHA Heart Disease & Stroke Statistics, 2010 Update), it was estimated that approximately 81,100,000 Americans had one or more forms of cardiovascular disease (CVD).  This number is expected to rise as the population continues to age adding increased cost pressure to a healthcare system already financially challenged.  The cost of cardiovascular diseases and stroke in 2008 is estimated by the American Heart Association at $448.5 billion which is almost a quarter of the annual $2 trillion estimated healthcare dollar. VectraCor has developed a technology that may have a significant impact on lowering diagnostic costs while potentially improving cardiac diagnosis and patient care in the CVD sector.

VectraCor, Inc. is a New Jersey-based medical device company that has intellectual property in the area of diagnostic cardiology.  The technology is patented or pending in over 12 countries.   We have over 40 published papers or abstracts on the technology and have presented at the American College of Cardiology (ACC), Society of Critical Care Medicine (SCCM) and American College of Emergency Physicians.

If you are interested in VectraCor and reading the Business Plan, please contact
Brad S. Schreck at 973-904-0444 or e-mail bschreck@vectracor.com.

» Disruptive Technology
» Patent Protection
» Publications Validating Technology
» Proven Reimbursement
» Large Market Potential
» Strong Respected Medical Advisory Board
» Experienced Management Team

VectraCor, Inc.
785 Totowa Road
Suite 100
Totowa, NJ 07512
973-904-0444  Office

973-768-0402  Mobile
Executive Summary can be furnished upon request.  Please click here for to request: